# TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

> **NCT05268926** · PHASE2 · TERMINATED · sponsor: **University Medical Center Groningen** · enrollment: 9 (actual)

## Conditions studied

- Albuminuria

## Interventions

- **DRUG:** Dapagliflozin 10Mg Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05268926
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-03
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-02-02
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to a delayed start-up and delayed patient inclusion in combination with new available scientific data, continuation of the clinical study no longer serves a scientific purpose.
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268926, "TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05268926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*